NEW YORK, Oct. 16, 2017 /PRNewswire/ -- Hoth
Therapeutics Inc., a Nevada
corporation ("Hoth" or the "Company"), a development stage
biopharmaceutical company focused on unique targeted therapeutics
for patients suffering from indications such as atopic dermatitis,
also known as eczema, announced today the addition of Dr.
Richard D. Granstein, M.D., to the
Company's Technology Advisory Board. The Technology Advisory
Board was formed to assist the Company in developing the BioLexa
Platform. The BioLexa Platform is a proprietary, patented,
drug compound platform developed at the University of Cincinnati.
Robb Knie, CEO of Hoth stated,
"We are continuing to leverage the investment made by Spherix
Incorporated (NASDAQ: SPEX) to expand and grow the BioLexa Platform
by adding Dr. Granstein to our Technology Advisory Board. Dr.
Granstein is one of the nation's most esteemed dermatologist and
the current Chairman of the Department of Dermatology at Weill
Cornell Medical Center. His extensive and prestigious
background studying skin disorders will be invaluable to the
Company in our attempt to bring relief to the approximately 32
million Americans suffering from eczema."
Richard D. Granstein, M.D. is the
George W. Hambrick, Jr. Professor and Chairman of the Department of
Dermatology. Dr. Granstein obtained his undergraduate education at
the Massachusetts Institute of
Technology and his medical education at the UCLA School of
Medicine. After completing his internship in 1979, he trained in
dermatology at the Massachusetts
General Hospital. As a Research Fellow, Dr. Granstein studied
immunology and tumor biology at the National Cancer
Institute-Frederick Cancer Research Facility and at Harvard Medical School. Dr. Granstein joined the
faculty of the Department of Dermatology at Harvard Medical School and the Massachusetts General Hospital in 1984. In 1995 he
left Harvard to become Chairman of the
Department of Dermatology at the Weill Medical
College of Cornell University and Dermatologist-in-Chief at
the NewYork-Presbyterian/Weill Cornell Medical Center.
Dr. Granstein's research interests center on the regulation of
immunity within the skin and the relationship of the skin's immune
system to the development of skin cancers. He also has a special
research interest in the regulation of the immune system by stress
and the nervous system. He was the first to demonstrate that
certain immune cells within the skin are capable of initiating an
immune response against a malignant tumor and that immune cells
within the epidermis (the upper layer of the skin) have an anatomic
relationship with nerves and can be regulated by proteins produced
by those nerves. His clinical interests include autoimmune
disorders of the skin, skin cancer, and psoriasis.
About Hoth Therapeutics Incorporated
Hoth Therapeutics Inc., a Nevada corporation, is a development stage
biopharmaceutical company focused on unique targeted therapeutics
for patients suffering from indications such as atopic dermatitis,
also known as eczema.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. We are a small
company with limited financial resources and our scientific
background and abilities to implement a commercialization strategy
is subject to ever-changing market conditions and rapidly-advancing
technologies over which we have no control. While we believe that
these forward-looking statements are reasonable, market conditions
and competition in the marketplace is ever-changing and we have no
control over these influences. As a result, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to us on the date of this release.
These forward looking statements are based upon current estimates
and assumptions and are subject to various risks and uncertainties,
including without limitation those set forth in the Company's
filings with the Securities and Exchange Commission (the "SEC")
including, but not limited to, the Risk Factors relating to the
Company's patent business and other aspects of the Company's
business contained therein. Thus, actual results could be
materially different. The Company expressly disclaims any
obligation to update or alter statements whether as a result of new
information, future events or otherwise, except as required by
law.
Contact:
Hoth Therapeutics, Inc.
investorrelations@hoththerapeutics.com
646-722-2899
www.hoththerapeutics.com
View original
content:http://www.prnewswire.com/news-releases/hoth-therapeutics-inc-announces-the-addition-of-dr-richard-d-granstein-md-to-the-companys-technology-advisory-board-300536339.html
SOURCE Hoth Therapeutics Inc.